Cargando…
Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors
Although mutational inactivation of p53 is found in 50% of all human tumors, a subset of tumors display defective p53 function, but retain wild-type (WT) p53. Here, direct and indirect mechanisms leading to the loss of WT p53 activities are discussed. We summarize the oncogenic roles of iASPP, an in...
Autores principales: | Dong, Peixin, Ihira, Kei, Hamada, Junichi, Watari, Hidemichi, Yamada, Takahiro, Hosaka, Masayoshi, Hanley, Sharon J.B., Kudo, Masataka, Sakuragi, Noriaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652980/ https://www.ncbi.nlm.nih.gov/pubmed/26343523 |
Ejemplares similares
-
Suppression of iASPP-dependent aggressiveness in cervical cancer through reversal of methylation silencing of microRNA-124
por: Dong, Peixin, et al.
Publicado: (2016) -
Regulation of immunological tolerance by the p53-inhibitor iASPP
por: Akama-Garren, Elliot H., et al.
Publicado: (2023) -
Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression
por: Dong, Peixin, et al.
Publicado: (2016) -
p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer
por: Miller, Paul, et al.
Publicado: (2023) -
Caspase cleavage of iASPP potentiates its ability to inhibit p53 and NF-κB
por: Hu, Ying, et al.
Publicado: (2015)